PL2970255T3 - Związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych - Google Patents

Związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych

Info

Publication number
PL2970255T3
PL2970255T3 PL14708291T PL14708291T PL2970255T3 PL 2970255 T3 PL2970255 T3 PL 2970255T3 PL 14708291 T PL14708291 T PL 14708291T PL 14708291 T PL14708291 T PL 14708291T PL 2970255 T3 PL2970255 T3 PL 2970255T3
Authority
PL
Poland
Prior art keywords
compounds
treatment
pharmaceutical compositions
inflammatory disorders
disorders
Prior art date
Application number
PL14708291T
Other languages
English (en)
Inventor
Nicolas Desroy
Bertrand Heckmann
Reginald Christophe Xavier Brys
Agnès Joncour
Christophe Peixoto
Xavier Bock
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of PL2970255T3 publication Critical patent/PL2970255T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL14708291T 2013-03-14 2014-03-07 Związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych PL2970255T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361781174P 2013-03-14 2013-03-14
PCT/EP2014/054440 WO2014139882A1 (en) 2013-03-14 2014-03-07 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP14708291.1A EP2970255B9 (en) 2013-03-14 2014-03-07 Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number Publication Date
PL2970255T3 true PL2970255T3 (pl) 2017-10-31

Family

ID=50236198

Family Applications (2)

Application Number Title Priority Date Filing Date
PL14708291T PL2970255T3 (pl) 2013-03-14 2014-03-07 Związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych
PL17177371T PL3269716T3 (pl) 2013-03-14 2014-03-07 Nowe związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17177371T PL3269716T3 (pl) 2013-03-14 2014-03-07 Nowe związki i ich kompozycje farmaceutyczne do leczenia zaburzeń zapalnych

Country Status (29)

Country Link
US (7) US8993590B2 (pl)
EP (3) EP3269716B1 (pl)
JP (2) JP6339595B2 (pl)
KR (2) KR20210034098A (pl)
CN (1) CN105143221B (pl)
AR (1) AR095280A1 (pl)
AU (3) AU2014231009B2 (pl)
BR (1) BR112015020998B1 (pl)
CA (1) CA2902103C (pl)
CY (2) CY1119352T1 (pl)
DK (2) DK3269716T3 (pl)
ES (2) ES2824723T3 (pl)
HR (2) HRP20171219T1 (pl)
HU (2) HUE051195T2 (pl)
IL (2) IL240531B (pl)
LT (2) LT2970255T (pl)
MX (1) MX358342B (pl)
MY (1) MY170260A (pl)
NZ (1) NZ711202A (pl)
PH (1) PH12015502055B1 (pl)
PL (2) PL2970255T3 (pl)
PT (2) PT2970255T (pl)
RU (1) RU2675818C2 (pl)
SG (1) SG11201507224RA (pl)
SI (2) SI2970255T1 (pl)
TW (2) TWI695002B (pl)
UY (1) UY35437A (pl)
WO (1) WO2014139882A1 (pl)
ZA (1) ZA201505909B (pl)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012308570B2 (en) 2011-09-14 2016-11-10 Samumed, Llc Indazole-3-carboxamides and their use as Wnt/b-catenin signaling pathway inhibitors
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
HUE051195T2 (hu) 2013-03-14 2021-03-01 Galapagos Nv Új vegyületek és gyógyászati készítményeik gyulladásos rendellenességek kezelésére
US9796719B2 (en) 2013-06-19 2017-10-24 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CA2927541C (en) 2013-10-15 2021-06-08 Radux Devices, LLC Securing a medical device to a valve instrument
MX386798B (es) 2014-08-29 2025-03-19 Chdi Foundation Inc Sondas para la proyección de imagen de la proteína huntingtina.
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CA2988306A1 (en) 2015-06-05 2016-12-08 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of demyelinating diseases
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
US10195185B2 (en) 2015-08-03 2019-02-05 Samumed, Llc 3-(1H-imidazo[4,5-C]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10226448B2 (en) 2015-08-03 2019-03-12 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
US10350199B2 (en) 2015-08-03 2019-07-16 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10285983B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017024004A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10463651B2 (en) 2015-08-03 2019-11-05 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
WO2017023980A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
WO2017024015A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
CN108473491A (zh) * 2015-11-06 2018-08-31 萨穆梅德有限公司 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途
US11065251B2 (en) 2016-05-06 2021-07-20 Albert Einstein College Of Medicine PAK1 inhibitors and uses thereof
DK3464285T3 (da) 2016-06-01 2022-12-19 Biosplice Therapeutics Inc Fremgangsmåde til fremstilling af n-(5-(3-(7-(3-fluorphenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamid
EP3528808B1 (en) 2016-10-21 2021-10-06 BioSplice Therapeutics, Inc. Methods of using indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
WO2018080572A1 (en) 2016-10-24 2018-05-03 Precision Combustion, Inc. Regenerative solid oxide stack
MA46696A (fr) 2016-11-07 2019-09-11 Samumed Llc Formulations injectables à dose unique prêtes à l'emploi
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
GB201710851D0 (en) 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
WO2019029620A1 (zh) * 2017-08-09 2019-02-14 广州市恒诺康医药科技有限公司 Atx抑制剂及其制备方法和应用
MX2020001199A (es) * 2017-08-09 2020-03-24 Galapagos Nv Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
CN111343986A (zh) 2017-11-15 2020-06-26 加拉帕戈斯股份有限公司 用于治疗纤维化疾病的化合物及其药物组合物
EP3753943A4 (en) * 2018-02-14 2021-06-23 Suzhou Sinovent Pharmaceuticals Co., Ltd. HETEROCYCLIC COMPOUND, ITS APPLICATION AND PHARMACEUTICAL COMPOSITION CONSISTING OF IT
AU2019272377B2 (en) * 2018-05-24 2022-03-10 Guangzhou Henovcom Bioscience Co., Ltd. Heteroaromatic compounds, pharmaceutical compositions and uses thereof
JP2021526123A (ja) * 2018-05-29 2021-09-30 シーチュアン ハイスコ ファーマシューティカル シーオー．，エルティーディー． オートタキシン阻害剤とその使用
ES2952939T3 (es) 2018-07-27 2023-11-07 Mitsubishi Tanabe Pharma Corp Derivados novedosos de piridina 3,5-disustituida y piridazina 3,5-disustituida y uso farmacéutico de los mismos
GB201812861D0 (en) 2018-08-08 2018-09-19 Galapagos Nv Methods of administering therapy
US11104665B2 (en) 2018-10-29 2021-08-31 Boehringer Ingelheim International Gmbh Pyridazines
KR20210108414A (ko) 2018-12-25 2021-09-02 솔-겔 테크놀로지스 리미티드 Egfr 억제제를 포함하는 조성물에 의한 피부 장애 치료
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN113874354B (zh) * 2019-06-04 2024-02-20 江苏恒瑞医药股份有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用
WO2021034414A2 (en) * 2019-07-03 2021-02-25 Cornell University Modulation of dendritic cell function by the phospholipid messenger lpa
US11465982B2 (en) 2019-07-22 2022-10-11 Boehringer Ingelheim International Gmbh Pyridazines
DK4003978T3 (da) 2019-07-22 2024-07-22 Boehringer Ingelheim Int N-methyl, n-(6-(methoxy)pyridazin-3-yl) aminderivater som autotaxin (atx) modulatorer til behandlingen af inflammatoriske luftvejs- eller fibrotiske sygdomme
US11485727B2 (en) 2019-07-22 2022-11-01 Boehringer Ingelheim International Gmbh N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (ATX) modulators
EP3782997A1 (en) 2019-08-19 2021-02-24 Galapagos N.V. Fused pyrimidine compounds and pharmaceutical compositions thereof for the treatment of fibrotic diseases
IL291114B2 (en) * 2019-09-06 2025-09-01 Wuhan Humanwell Innovative Drug Res And Development Center Limited Company Pyrimidine compound and method for preparing same
CN112778334B (zh) * 2019-11-07 2022-04-15 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
CN111004235A (zh) * 2019-11-29 2020-04-14 沈阳药科大学 一种ATX抑制剂Ziritaxestat的合成方法
CN113493453B (zh) * 2020-04-07 2023-06-16 江苏恒瑞医药股份有限公司 稠合芳香环类衍生物、其制备方法及其在医药上的应用
TW202202499A (zh) * 2020-07-09 2022-01-16 大陸商蘇州愛科百發生物醫藥技術有限公司 一種atx抑制劑及其製備方法和應用
CN114315825A (zh) * 2020-09-30 2022-04-12 江西济民可信集团有限公司 吡啶并咪唑衍生物及其制备方法和应用
AR123686A1 (es) 2020-10-06 2023-01-04 Ildong Pharmaceutical Co Ltd Compuestos inhibidores de la autotaxina
CN116437917B (zh) * 2020-11-04 2024-12-13 西藏海思科制药有限公司 Atx抑制剂氘代衍生物及其应用
CA3199039A1 (en) * 2020-11-16 2022-05-19 Qingan ZOU Imidazothiazole compounds, pharmaceutical compositions, and uses thereof
PT4274572T (pt) 2021-01-05 2026-03-11 Zydus Lifesciences Ltd Novos inibidores da autotaxina
KR20230153387A (ko) 2021-02-02 2023-11-06 리미널 바이오사이언시스 리미티드 Gpr84 길항제 및 이의 용도
JP2024506858A (ja) 2021-02-02 2024-02-15 リミナル・バイオサイエンシーズ・リミテッド Ｇｐｒ８４アンタゴニストおよびその使用
CA3239101A1 (en) * 2021-11-25 2023-06-01 Gang Deng Tricyclic derivative and preparation method therefor and application thereof
WO2023235871A2 (en) * 2022-06-03 2023-12-07 Seer, Inc. Systems, compositions, and methods relating to neurodegenerative diseases
KR102587919B1 (ko) * 2022-07-22 2023-10-11 주식회사 넥스트젠바이오사이언스 신규한 헤테로사이클릭 화합물 및 이를 포함하는 오토탁신 저해용 약학 조성물
JP2025527250A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド ヘテロアリールカルボキサミド及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
JP2025527248A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド 置換ピリドンｇｐｒ８４アンタゴニスト及びその使用
JP2025527247A (ja) 2022-08-02 2025-08-20 リミナル・バイオサイエンシーズ・リミテッド アリール－トリアゾリル及び関連するｇｐｒ８４アンタゴニストならびにそれらの使用
GR1010570B (el) 2022-12-22 2023-11-17 Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., 4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1218382E (pt) * 1999-10-08 2004-06-30 Gruenenthal Gmbh Derivados de imidazo-3-il-amina biciclica
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
US20080015193A1 (en) * 2006-06-20 2008-01-17 Mendoza Jose S Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
WO2008138842A1 (en) * 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
DE102008059578A1 (de) 2008-11-28 2010-06-10 Merck Patent Gmbh Benzo-Naphtyridin Verbindungen
EA201100879A1 (ru) * 2008-12-01 2012-01-30 Мерк Патент Гмбх Производные пиридопиримидина в качестве ингибиторов аутотаксина
CA2757415C (en) 2009-04-02 2018-02-06 Merck Patent Gmbh Autotaxin inhibitors
TW201120043A (en) * 2009-11-05 2011-06-16 Galapagos Nv Fused pyrazine compounds as their salts, useful for the treatment of degenerative and inflammatory diseases
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
ES2646834T3 (es) * 2010-08-20 2017-12-18 Amira Pharmaceuticals, Inc. Inhibidores de autotaxina y usos de los mismos
US20130052190A1 (en) * 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
US9260416B2 (en) * 2011-05-27 2016-02-16 Amira Pharmaceuticals, Inc. Heterocyclic autotaxin inhibitors and uses thereof
HUE051195T2 (hu) * 2013-03-14 2021-03-01 Galapagos Nv Új vegyületek és gyógyászati készítményeik gyulladásos rendellenességek kezelésére

Also Published As

Publication number Publication date
EP2970255B9 (en) 2018-09-19
MX358342B (es) 2018-08-15
NZ711202A (en) 2019-04-26
MX2015011077A (es) 2015-10-29
LT3269716T (lt) 2020-10-26
EP2970255A1 (en) 2016-01-20
AU2017286828A1 (en) 2018-01-18
AU2019204539B2 (en) 2021-01-21
SG11201507224RA (en) 2015-10-29
WO2014139882A1 (en) 2014-09-18
SI3269716T1 (sl) 2020-12-31
PL3269716T3 (pl) 2021-02-08
RU2015143430A (ru) 2017-04-18
DK2970255T3 (en) 2017-09-18
EP3269716B1 (en) 2020-09-16
IL240531B (en) 2018-01-31
CN105143221A (zh) 2015-12-09
AU2014231009B2 (en) 2017-10-05
CY1119352T1 (el) 2018-02-14
RU2675818C2 (ru) 2018-12-25
ES2638980T3 (es) 2017-10-24
AR095280A1 (es) 2015-09-30
MY170260A (en) 2019-07-13
IL256624A (en) 2018-02-28
US10526329B2 (en) 2020-01-07
PH12015502055A1 (en) 2016-01-18
US20160244443A1 (en) 2016-08-25
EP2970255B1 (en) 2017-08-02
AU2019204539A1 (en) 2019-07-18
HRP20201641T1 (hr) 2020-12-25
ZA201505909B (en) 2021-09-29
JP2016512208A (ja) 2016-04-25
JP6517976B2 (ja) 2019-05-22
JP2018135350A (ja) 2018-08-30
JP6339595B2 (ja) 2018-06-06
BR112015020998B1 (pt) 2022-10-18
US20150111872A1 (en) 2015-04-23
IL256624B (en) 2019-09-26
CA2902103C (en) 2021-09-21
US9670204B2 (en) 2017-06-06
KR20150128995A (ko) 2015-11-18
TW201444835A (zh) 2014-12-01
US9249141B2 (en) 2016-02-02
US20190169184A1 (en) 2019-06-06
US10125132B2 (en) 2018-11-13
ES2824723T3 (es) 2021-05-13
PT3269716T (pt) 2020-10-09
KR20210034098A (ko) 2021-03-29
AU2014231009A1 (en) 2015-09-10
CY1123521T1 (el) 2022-03-24
HK1249507A1 (en) 2018-11-02
BR112015020998A2 (pt) 2017-07-18
US8993590B2 (en) 2015-03-31
CN105143221B (zh) 2017-06-09
AU2017286828B2 (en) 2019-04-04
TW201936604A (zh) 2019-09-16
HRP20171219T1 (hr) 2017-11-03
HK1219730A1 (en) 2017-04-13
DK3269716T3 (da) 2020-10-19
UY35437A (es) 2014-10-31
LT2970255T (lt) 2017-12-11
PT2970255T (pt) 2017-09-05
EP3269716A1 (en) 2018-01-17
IL240531A0 (en) 2015-10-29
US20170362227A1 (en) 2017-12-21
EP3760630A1 (en) 2021-01-06
US20230022534A1 (en) 2023-01-26
CA2902103A1 (en) 2014-09-18
KR102231637B1 (ko) 2021-03-25
HUE035966T2 (en) 2018-05-28
US20140303140A1 (en) 2014-10-09
SI2970255T1 (sl) 2017-12-29
US11072611B2 (en) 2021-07-27
TWI749290B (zh) 2021-12-11
PH12015502055B1 (en) 2016-01-18
US20200239466A1 (en) 2020-07-30
HUE051195T2 (hu) 2021-03-01
TWI695002B (zh) 2020-06-01

Similar Documents

Publication Publication Date Title
IL256624B (en) Pharmaceutical compounds and preparations thereof for the treatment of inflammatory disorders
IL246833A0 (en) New salts and their pharmaceutical preparations for the treatment of inflammatory disorders
IL255109A0 (en) New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
GB201402070D0 (en) Pharmaceutical compositions for the treatment of inflammatory disorders
IL241264A0 (en) Compounds and compositions for the treatment of parasitic diseases
GB201411241D0 (en) Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
GB201401086D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
SI3369435T1 (sl) Sestavek za zdravljenje vnetne bolezni sklepov
GB201315079D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314016D0 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases
GB201314015D0 (en) Novel compound useful for the treatment of degenerative and inflammatory diseases